The ACIP release guidelines for the 2020-2021 vaccination recommendations; In COVID, there’s developments in convalescent plasma authorization, a 15 minute test, and ethnobotanist’s give a stark warning concerning a plant that some are touting as a cure. In other news an intrauterine device gains expanded approval and there’s a label update for hydrochlorothiazide.
Hydrochlorothiazide is indicated for the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives.
The approval was based on data from the multicenter, double-blind, placebo-controlled phase 3 IMspire150 study.
Use supported regardless of BRAF V600E/K mutation status, receipt of prior BRAFi with/without MEKi
The FDA has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
Odds of developing ICI colitis significantly reduced with vitamin D use in patients with melanoma
The FDA has approved the supplemental Biologics License Application (sBLA) for Keytruda® (Merck) to include an additional recommended dosage of 400mg every 6 weeks across all adult indications.
Risks increased for skin cancer and GI, pulmonary, infectious, hematologic adverse events
This slideshow shows drug information for Rozlytrek. Click here for the complete Rozlytrek monograph.
The Food and Drug Administration (FDA) has granted accelerated approval to Rozlytrek (entrectinib; Genentech)
